Valuation: 3billion, Inc.

Market Cap 201B 142M 123M 115M 105M 198M 13.56B 201M 1.36B 531M 6.79B 533M 522M 22.64B P/E 2025
-107x
P/E 2026 * -
Enterprise Value 185M 130K 113K 106K 96.43K 181K 12.42M 184K 1.25M 486K 6.22M 489K 478K 20.74M EV / Sales 2025
49x
EV / Sales 2026 * -
Free-Float
75.48%
Yield 2025 *
-
Yield 2026 * -
1 day-2.16%
1 week+0.80%
Current month+23.15%
1 month+12.23%
3 months-41.87%
6 months-54.26%
Current year-65.28%
1 week 6,110
Extreme 6110
6,660
1 month 4,260
Extreme 4260
6,660
Current year 4,260
Extreme 4260
18,690
1 year 4,260
Extreme 4260
20,100
3 years 3,025
Extreme 3025
20,100
5 years 3,025
Extreme 3025
20,100
10 years 3,025
Extreme 3025
20,100
Manager TitleAgeSince
Chief Executive Officer 45 2016-10-09
Director of Finance/CFO 46 2020-09-30
Chief Tech/Sci/R&D Officer 46 2018-07-31
Director TitleAgeSince
Director/Board Member 45 2016-10-09
Director/Board Member 44 2016-10-09
Director/Board Member 44 2020-11-17
Date Insider Type Main position Quantity % Market Cap.
4/16/25 Others

Chief Financial Officer

44,000 0.1387%
3/7/25 Fiscal year

Chief Financial Officer

40,000 0.1262%
3/7/25 Fiscal year 10,000 0.0316%
Change 5-day change 1-year change 3-year change Capi.($)
-2.16%+0.80%+2.76% - 145M
-3.13%+3.64%+88.15%+288.25% 4.03B
-4.66%-7.69%+38.85%+69.38% 3.59B
-3.26%+4.99%+166.12%-7.65% 3.05B
+0.15%+5.74%+290.60%+432.36% 2.45B
+3.97%+10.19%-19.73%-28.79% 2.3B
-3.75%+5.87%+9.27% - 1.3B
-0.16%+11.15%+13.73%+44.02% 1.03B
0.00%-7.52%+110.18%-44.10% 861M
+0.75%+9.89%-35.73%-0.10% 563M
Average -1.22%+3.11%+66.42%+94.17% 1.93B
Weighted average by Cap. -1.80%+2.27%+91.58%+133.56%

Financials

2025 2026 *
Net sales 10.8B 7.62M 6.6M 6.19M 5.64M 10.62M 727M 10.79M 72.88M 28.45M 364M 28.6M 27.98M 1.21B -
Net income -5.8B -4.09M -3.55M -3.32M -3.03M -5.7M -390M -5.79M -39.14M -15.28M -195M -15.36M -15.03M -652M -
Net Debt -16.9B -11.92M -10.33M -9.69M -8.83M -16.62M -1.14B -16.88M -114M -44.52M -569M -44.75M -43.78M -1.9B -
Logo 3billion, Inc.
3Billion Inc is a Korea-based company principally engaged in the provision of genetic testing services. The Company is principally engaged in the provision of rare genetic disease diagnostic testing services. The Company is also engaged in the research and development of technology that automatically reads the pathogenicity of numerous genetic variants found in the genome.
Employees
-
Date Price Change Volume
26-08-13 ₩6,330.00 -2.16% 92,222
26-08-12 ₩6,470.00 +2.54% 128,581
26-08-11 ₩6,310.00 -0.63% 77,890
26-08-10 ₩6,350.00 +4.44% 131,741
26-08-07 ₩6,080.00 -3.18% 53,586

Annual profits - Rate of surprise

  1. Stock Market
  2. Stocks
  3. A394800 Stock